TOMI Environmental Solutions, Inc. (TOMZ) is a $22 million micro-cap based in Frederick, Maryland, that makes and licenses ionized hydrogen peroxide decontamination systems sold under the SteraMist brand, along with related consumables and decontamination services for hospitals, biosecurity labs, food processing, and industrial clients. In the first hour of Monday's session the stock traded at $2.27, down 9.92% from Friday's close of $2.52. The direction is unambiguously lower. No company-specific press release, SEC filing, or analyst revision was published ahead of the decline, so the move is best characterized as a retracement of Friday's sharp rebound rather than a reaction to new information.
The most recent verified fundamental update remains the preliminary third-quarter report issued after the close on November 12. Revenue of $2.49 million climbed 24% from $2.01 million a year earlier and 11% sequentially, the third consecutive quarter of sequential growth, while nine-month revenue rose 38% to $6.39 million. Gross margin held at 59.0%, operating expenses fell 7%, and income from operations reached $30,047 versus a loss of $321,415 in the prior-year quarter — the first positive operating result since the third quarter of 2024.
The rub is scale versus expectations. The $2.49 million top line landed roughly half a million dollars below the consensus estimate of about $3.01 million, and management flagged that the figures remain preliminary until its auditors complete a review of the accounting treatment for $2.5 million of converted notes. Cash generation is still not self-sustaining, and the $12 million full-year revenue target requires a heavy fourth quarter. Down 9.92%, the stock is giving back the gains booked on that report rather than pricing in a new disappointment.
Beyond the earnings backdrop, no verifiable catalyst explains the session's slide. The pattern is consistent with profit-taking after a vertical run: shares climbed from $1.39 on October 26 to an intraday high of $2.655 on November 13, a gain of more than 90%, and the stock has now logged eight sessions in the past 60 with absolute moves larger than Monday's. Thin liquidity amplifies the effect — with average volume near 31,000 shares and Monday's tape showing only a few hundred shares changing hands in early trade, modest sell orders move the quote disproportionately. The pullback is also consistent with a retracement toward the lower half of the post-earnings range, and with traders reducing risk ahead of the accounting clarification and any fourth-quarter financing.
Turnover was light rather than panicked, suggesting an absence of both conviction sellers and institutional participation. The move was company-specific: broad indices were not the driver, and there is no evidence the decline reflected sector-wide pressure on infection-control or environmental-services names. Technically, the pullback leaves the stock above its late-October base near $1.39 but below Friday's high of $2.655, keeping the $2.20–$2.30 area as the level where the post-earnings range has repeatedly found buyers and $2.65 as the immediate ceiling. The 52-week range of roughly $1.21 to $3.24 underscores how wide the swing bands are for this name.
The scale runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. The score is 20 out of 100. The verified news is modest in isolation: a preliminary quarterly report with real growth, a positive operating result, but a revenue miss and unaudited figures — material for a $22 million company, yet already absorbed by the market last week and not repeated on Monday.
Monday's 9.92% decline was roughly 2.3 times the stock's typical daily move of about 4.3%, and a move of that size or larger has occurred eight times in the last 60 sessions. A stock that routinely swings this much therefore scores low on anomaly, and the two components combine into a modest overall reading.
Attention turns to the fourth quarter, which must deliver roughly $5.6 million in revenue to meet the $12 million full-year target, and to the expected $5 million of purchase orders management discussed on the November 12 call, with two custom systems not scheduled for delivery until early and mid-2027. The company's auditors must complete the convertible-note review, an event that could restate equity and net loss figures. Financing is the other watch item: management has acknowledged exploring expanded credit facilities or another offering, and any equity raise would carry dilution risk. Commercial catalysts include the expanded AgriMist EPA registration, independent Listeria biofilm data, food-safety protocols with large processors, and international pharma traction in India and Europe. The single sell-side rating on the name remains a Buy, though a single analyst provides limited signal. Risks include Nasdaq listing compliance, service revenue growth of just 1%, working-capital strain, and continued losses.
Tickeron's Trending AI Robots page highlights the automated strategies posting the strongest results under present market conditions. The platform offers hundreds of AI trading bots covering thousands of tickers, but this curated section narrows the field to the top performers only. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so visitors can compare approaches and match them to their own objectives. Review the current leaders to see which strategies are working now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Stochastic Oscillator for TOMZ moved out of overbought territory on November 18, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 53 similar instances where the indicator exited the overbought zone. In 49 of the 53 cases the stock moved lower. This puts the odds of a downward move at 90%.
The 10-day RSI Indicator for TOMZ moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 26 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TOMZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
TOMZ broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on TOMZ as a result. In 68 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TOMZ just turned positive on October 27, 2026. Looking at past instances where TOMZ's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
TOMZ moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TOMZ crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +22.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where TOMZ advanced for three days, in 175 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 85 of 119 cases where TOMZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TOMZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.229) is normal, around the industry mean (10.189). P/E Ratio (-4.125) is within average values for comparable stocks, (-16.372). Projected Growth (PEG Ratio) (0.070) is also within normal values, averaging (0.975). Dividend Yield (0.000) settles around the average of (0.050) among similar stocks. P/S Ratio (1.637) is also within normal values, averaging (251.106).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TOMZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry IndustrialSpecialties